BCL2 and neoplasm: Similarly, antitumor activity and pharmacokinetics parameter of sequence-specific Bcl-2 antisense siRNA (BO43) and liposome complex could be improved through encapsulation of PEG into the surface of liposomal–siRNA complex by enhancing blood retention time, reducing the plasma clearance by the liver and thus, increasing accumulation of siRNA in the tumor region.